{
    "organizations": [],
    "uuid": "48949da556fc8deeeef86878dd2c503f2f5533ba",
    "author": "cnbc.com",
    "url": "http://www.cnbc.com/2018/03/21/pr-newswire-neovasc-announces-year-end-2017-financial-results-conference-call-and-webcast.html",
    "ord_in_thread": 0,
    "title": "Neovasc Announces Year End 2017 Financial Results Conference Call and Webcast",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "NASDAQ, TSX: NVCN\nVANCOUVER, March 21, 2018 /PRNewswire/ - Neovasc, Inc. (\"Neovasc\" or the \"Company\") (NASDAQ, TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies, today announced that it will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Wednesday, March 28, 2018.\nConference Call & Webcast\nWednesday, March 28 th @ 4:30pm Eastern Time\nDomestic:\n800-281-7973\nInternational:\n323-794-2093\nPasscode:\n4395026\nWebcast:\nhttp://public.viavid.com/index.php?id=128910\nReplays available through April 10:\nDomestic:\n844-512-2921\nInternational:\n412-317-6671\nConference ID:\n4395026\nAbout Neovasc Inc.\nNeovasc is a specialty medical device company that develops, manufactures and markets products for the rapidly growing cardiovascular marketplace. Its products include the Neovasc Reducer™, for the treatment of refractory angina, which is not currently available in the United States and has been available in Europe since 2015, and the Tiara™, for the transcatheter treatment of mitral valve disease, which is currently under clinical investigation in the United States, Canada and Europe. For more information, visit: www.neovasc.com .\nSOURCE Neovasc Inc.",
    "published": "2018-03-21T23:30:00.000+02:00",
    "crawled": "2018-03-22T02:31:43.005+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "nasdaq",
        "tsx",
        "nvcn",
        "vancouver",
        "march",
        "neovasc",
        "neovasc",
        "company",
        "nasdaq",
        "tsx",
        "nvcn",
        "leader",
        "development",
        "minimally",
        "invasive",
        "transcatheter",
        "mitral",
        "valve",
        "replacement",
        "technology",
        "today",
        "announced",
        "report",
        "financial",
        "result",
        "year",
        "ended",
        "december",
        "host",
        "conference",
        "call",
        "webcast",
        "eastern",
        "time",
        "wednesday",
        "march",
        "conference",
        "call",
        "webcast",
        "wednesday",
        "march",
        "th",
        "eastern",
        "time",
        "domestic",
        "international",
        "passcode",
        "webcast",
        "http",
        "replay",
        "available",
        "april",
        "domestic",
        "international",
        "conference",
        "id",
        "neovasc",
        "neovasc",
        "specialty",
        "medical",
        "device",
        "company",
        "develops",
        "manufacture",
        "market",
        "product",
        "rapidly",
        "growing",
        "cardiovascular",
        "marketplace",
        "product",
        "include",
        "neovasc",
        "treatment",
        "refractory",
        "angina",
        "currently",
        "available",
        "united",
        "state",
        "available",
        "europe",
        "since",
        "transcatheter",
        "treatment",
        "mitral",
        "valve",
        "disease",
        "currently",
        "clinical",
        "investigation",
        "united",
        "state",
        "canada",
        "europe",
        "information",
        "visit",
        "source",
        "neovasc",
        "inc"
    ]
}